Gastroenterology report
Cure8 research brief
Limited source text
What Cure8 can confirm
What We Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Medications. Use the original source link for the full details.
What Is Not Available
The source did not provide enough reliable article text for a source-grounded Cure8 brief. Study details, results, and limitations should be checked in the original source.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationGastroenterology report
AuthorsJulien Moragny, Emeline Delabre, Florine Foré +3 more
InstitutionPharmacovigilance Centre, Department of Clinical Pharmacology, Amiens-Picardie University Hospital, F-80054, Amiens, France.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedOct 6, 2026, 12:00 AM
Content availableMetadata only
Conflict statement: None declared.
Cure8 could not retrieve enough reliable source text to summarize this article. This page is based on the article title, source metadata, and Cure8 topic classification.
Comments on "Ustekinumab-induced Henoch-Schönlein purpura in Crohn's disease: a case report and literature review".
Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Ustekinumab. The original article is from Intestinal research.
Severe upadacitinib-induced anemia in a multi-refractory Crohn’s disease patient – a case report
This case shows that upadacitinib, a JAK inhibitor used for refractory IBD, can cause severe anemia in rare cases but that dose reduction (rather than permanent discontinuation) may reversibly restore blood counts while...
Dual-Targeted Therapy With Upadacitinib and Ustekinumab in Pediatric Refractory Perianal Crohn's Disease
This report describes combined use of upadacitinib and ustekinumab to treat severe, refractory perianal Crohn’s disease in an adolescent — a scenario many patients and caregivers find especially difficult to manage.